TGF-β-3 Induces Different Effects from TGF-β-1 and -2 on Cellular Metabolism and the Spatial Properties of the Human Trabecular Meshwork Cells.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
20 Feb 2023
Historique:
received: 14 01 2023
revised: 15 02 2023
accepted: 18 02 2023
entrez: 25 2 2023
pubmed: 26 2 2023
medline: 3 3 2023
Statut: epublish

Résumé

To compare the effects among three TGF-β isoforms (TGF-β-1, TGF-β-2, and TGF-β-3) on the human trabecular meshwork (HTM), two-dimensional (2D) and three-dimensional (3D) cultures of commercially available certified immortalized HTM cells were used, and the following analyses were conducted: (1) trans-endothelial electrical resistance (TEER) and FITC dextran permeability measurements (2D); (2) a real-time cellular metabolic analysis (2D); (3) analysis of the physical property of the 3D HTM spheroids; and (4) an assessment of the gene expression levels of extracellular matrix (ECM) components (2D and 3D). All three TGF-β isoforms induced a significant increase in TEER values and a relative decrease in FITC dextran permeability in the 2D-cultured HTM cells, but these effects were the most potent in the case of TGF-β-3. The findings indicated that solutions containing 10 ng/mL of TGF-β-1, 5 ng/mL of TGF-β-2, and 1 ng/mL of TGF-β-3 had nearly comparable effects on TEER measurements. However, a real-time cellular metabolic analysis of the 2D-cultured HTM cells under these concentrations revealed that TGF-3-β induced quite different effects on the metabolic phenotype, with a decreased ATP-linked respiration, increased proton leakage, and decreased glycolytic capacity compared with TGF-β-1 and TGF-β-2. In addition, the concentrations of the three TGF-β isoforms also caused diverse effects on the physical properties of 3D HTM spheroids and the mRNA expression of ECMs and their modulators, in many of which, the effects of TGF-β-3 were markedly different from TGF-β-1 and TGF-β-2. The findings presented herein suggest that these diverse efficacies among the TGF-β isoforms, especially the unique action of TGF-β-3 toward HTM, may induce different effects within the pathogenesis of glaucoma.

Identifiants

pubmed: 36835591
pii: ijms24044181
doi: 10.3390/ijms24044181
pmc: PMC9960590
pii:
doi:

Substances chimiques

Transforming Growth Factor beta2 0
Transforming Growth Factor beta1 0
fluorescein isothiocyanate dextran 0
Transforming Growth Factor beta3 0
Protein Isoforms 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Biomedicines. 2021 Jul 31;9(8):
pubmed: 34440134
Invest Ophthalmol Vis Sci. 2016 Nov 01;57(14):5984-5995
pubmed: 27820954
J Glaucoma. 2014 Oct-Nov;23(8 Suppl 1):S12-4
pubmed: 25275897
Ophthalmic Res. 2021;64(1):62-67
pubmed: 32259818
Exp Eye Res. 2003 Dec;77(6):757-65
pubmed: 14609564
Mol Vis. 2021 Jan 20;27:61-77
pubmed: 33633440
Mol Vis. 2015 May 25;21:612-20
pubmed: 26019480
Sci Rep. 2022 Sep 26;12(1):16006
pubmed: 36163231
Mol Vis. 2012;18:431-8
pubmed: 22355254
Ophthalmology. 2005 Jul;112(7):1177-85
pubmed: 15921747
Bioengineering (Basel). 2022 Jul 12;9(7):
pubmed: 35877361
J Glaucoma. 2018 Jul;27 Suppl 1:S54-S60
pubmed: 29401156
Exp Eye Res. 2018 Jun;171:164-173
pubmed: 29526795
Cells. 2022 Jan 16;11(2):
pubmed: 35053416
Clin Exp Ophthalmol. 2022 Mar;50(2):163-182
pubmed: 35037377
Sci Rep. 2020 May 14;10(1):7958
pubmed: 32409724
J Biol Chem. 2013 Nov 1;288(44):32074-92
pubmed: 24056369
Exp Eye Res. 2001 Dec;73(6):765-80
pubmed: 11846508
Endocrinology. 2019 Jan 1;160(1):20-35
pubmed: 30388216
Graefes Arch Clin Exp Ophthalmol. 2001 Feb;239(2):109-13
pubmed: 11372538
Sci Rep. 2016 Jan 19;6:19640
pubmed: 26782355
Am J Ophthalmol. 2010 May;149(5):704-12
pubmed: 20399924
Invest Ophthalmol Vis Sci. 2015 Jun;56(6):3860-8
pubmed: 26066753
J Cell Sci. 2002 May 15;115(Pt 10):2189-98
pubmed: 11973359
Sci Rep. 2021 Jan 14;11(1):1408
pubmed: 33446826
Nat Cell Biol. 1999 Sep;1(5):260-6
pubmed: 10559937
Int J Mol Sci. 2021 Dec 07;22(24):
pubmed: 34947978
Molecules. 2021 Oct 22;26(21):
pubmed: 34770791
Respir Res. 2002;3:1
pubmed: 11806836
Graefes Arch Clin Exp Ophthalmol. 2017 Sep;255(9):1763-1769
pubmed: 28660443
Sci Rep. 2021 Jul 27;11(1):15286
pubmed: 34315994
Int J Mol Sci. 2022 May 26;23(11):
pubmed: 35682657
Am J Pathol. 2010 Jun;176(6):2868-79
pubmed: 20395431
Sci Rep. 2020 Sep 24;10(1):15641
pubmed: 32973273
J Biol Chem. 2018 Jun 22;293(25):9854-9868
pubmed: 29743238
Biomedicines. 2022 Jun 06;10(6):
pubmed: 35740359
Biomolecules. 2020 Mar 23;10(3):
pubmed: 32210029
Exp Eye Res. 2017 May;158:112-123
pubmed: 27443500
J Ocul Pharmacol Ther. 2014 Mar-Apr;30(2-3):154-62
pubmed: 24517218
Br J Ophthalmol. 2006 Mar;90(3):262-7
pubmed: 16488940
Hepatology. 2006 Dec;44(6):1487-501
pubmed: 17133487
J Biomed Sci. 2021 Jun 17;28(1):47
pubmed: 34140021
Sci Rep. 2021 Sep 29;11(1):19369
pubmed: 34588570
Methods Cell Biol. 2020;156:271-307
pubmed: 32222223
Growth Factors. 2007 Jun;25(3):160-7
pubmed: 18049952
PLoS One. 2021 Apr 29;16(4):e0249759
pubmed: 33914756
Int J Mol Med. 2018 Mar;41(3):1201-1212
pubmed: 29286147
Cells. 2021 Dec 07;10(12):
pubmed: 34943956
Int J Mol Sci. 2022 May 13;23(10):
pubmed: 35628282
Invest Ophthalmol Vis Sci. 2003 May;44(5):2118-25
pubmed: 12714651
Sci Rep. 2020 Nov 20;10(1):20292
pubmed: 33219246
Invest Ophthalmol Vis Sci. 2020 Jun 3;61(6):13
pubmed: 32503053
Lancet. 2004 May 22;363(9422):1711-20
pubmed: 15158634
Lancet. 2009 Apr 11;373(9671):1264-74
pubmed: 19362676
Invest Ophthalmol Vis Sci. 1998 Dec;39(13):2649-58
pubmed: 9856774
Cold Spring Harb Perspect Biol. 2016 May 02;8(5):
pubmed: 27141051
Clin Ophthalmol. 2014 Jan 29;8:305-9
pubmed: 24511224
Sci Rep. 2021 Apr 1;11(1):7319
pubmed: 33795740
Nature. 1985 Aug 22-28;316(6030):701-5
pubmed: 3861940
PLoS One. 2017 Aug 10;12(8):e0182571
pubmed: 28797085
Free Radic Biol Med. 2010 Jan 1;48(1):1-15
pubmed: 19800967
Trends Endocrinol Metab. 2012 Sep;23(9):451-8
pubmed: 22591987
J Cell Sci. 1995 Mar;108 ( Pt 3):985-1002
pubmed: 7542672

Auteurs

Megumi Watanabe (M)

Departments of Ophthalmology, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Japan.

Tatsuya Sato (T)

Departments of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, Sapporo 060-8556, Japan.
Departments of Cellular Physiology and Signal Transduction, Sapporo Medical University, Sapporo 060-8556, Japan.

Yuri Tsugeno (Y)

Departments of Ophthalmology, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Japan.

Megumi Higashide (M)

Departments of Ophthalmology, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Japan.

Masato Furuhashi (M)

Departments of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, Sapporo 060-8556, Japan.

Hiroshi Ohguro (H)

Departments of Ophthalmology, School of Medicine, Sapporo Medical University, Sapporo 060-8556, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH